Evidence map›Paper›PMID 29568993›Full record

ArticleCancer immunology, immunotherapy : CII2018

Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination.

Kazuyoshi Takeda, Kazutaka Kitaura, Ryuji Suzuki, Yuki Owada, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Takuya Tsunoda and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Kazuyoshi TakedaDivision of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan. ktakeda@juntendo.ac.jp.ORCID 0000-0002-5539-310X
Kazutaka KitauraDepartment of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, 252-0392, Japan.
Ryuji SuzukiDepartment of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, 252-0392, Japan.
Yuki OwadaDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Satoshi MutoDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Naoyuki OkabeDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Takeo HasegawaDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Jun OsugiDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Mika HoshinoDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Takuya TsunodaDepartment of Clinical Immuno-oncology, Showa University, Setagaya-ku, Tokyo, 157-8577, Japan.
Ko OkumuraDepartment of Biofunctional Micribiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
Fukushima Medical University · JPJuntendo University · JPNational Sagamihara Hospital · JPShowa University · JP

Funding

Ministry of Education, Science, and Culture, Japan 15K14410
6 · The paper itself

Abstract

Therapeutic cancer peptide vaccination is an immunotherapy designed to elicit cytotoxic T-lymphocyte (CTL) responses in patients. A number of therapeutic vaccination trials have been performed, nevertheless there are only a few reports that have analyzed the T-cell receptors (TCRs) expressed on tumor antigen-specific CTLs. Here, we use next-generation sequencing (NGS) to analyze TCRs of vaccine-induced CTL clones and the TCR repertoire of bulk T cells in peripheral blood mononuclear cells (PBMCs) from two lung cancer patients over the course of long-term vaccine therapy. In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs. All URLC10-specific CTL clones tested showed Ca

Indexed as

Cancer VaccinesFemaleHumansLeukocytes, MononuclearLung NeoplasmsMaleCancer VaccinesCancer/testis antigenCTLNext-generation sequencingTCRTherapeutic vaccine

Identifiers

PMID29568993
PMCPMC11028142
OpenAlexW2789481083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.